Capricor Therapeutics Inc

Capricor Therapeutics Inc. a clinical-stage biotechnology company focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate CAP-1002 an allogeneic cardiac-derived cell therapy which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX an engineered exosome platform technology which generated two vaccine candidates such as STX-S and STX-N induced an immune response against two SARS-CoV-2 proteins spike and nucleocapsid as well as developing vaccines and therapeutics for infectious and monogenic diseases and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston Inc. for the clinical manufacturing of CAP-1002 its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego California.